Is Intellia Therapeutics (NASDAQ:NTLA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Intellia Therapeutics at current levels.
First in vivo CRISPR approval is 18 months out and the market is pricing NTLA like it might never get there.
Where NTLA is headed
By mid-2028, Intellia should have the first in vivo CRISPR therapy approved anywhere in the world. Nex-z (NTLA-2001) for transthyretin amyloidosis is in three Phase 3 trials (MAGNITUDE for cardiomyopathy, MAGNITUDE-2 for polyneuropathy, and the ATTRv-PN readout feeding a 2027 BLA filing). A single infusion knocks down TTR protein by roughly 90% and holds. That is not a treatment. That is a functional cure competing directly with Alnylam's Amvuttra, which is currently doing over $1.5 billion annualised and requires quarterly injections forever. If nex-z lands with the efficacy the Phase 1 data suggests, Intellia captures a share of a market Alnylam is proving out for them, at a one-and-done price point somewhere north of $1 million per patient.
Read the full Compass Direction on NTLA
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios.
See the full NTLA analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Intellia Therapeutics (NASDAQ:NTLA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Intellia Therapeutics at current levels. First in vivo CRISPR approval is 18 months out and the market is pricing NTLA like it might never get there.
What is NTLA's Compass Score?
Intellia Therapeutics scores 41/100 on Alexandria's Compass, placing it in the "Neutral" tier. Scores blend eight factors and update weekly.
What is the price target for NTLA?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the NTLA page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.